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Health-sector reform in China and access to essential medicines
In 2009 the Chinese Government embarked on the most 
comprehensive health-sector reform since the economic 
reform of the 1970s, with a systematic plan to achieve 
universal health care by 2020. One of the key pillars of 
the reform is the establishment and implementation 
of a national essential medicines policy to ensure the 
safety, quality, supply, and aﬀ ordability of medicines. 
In this issue of The Lancet Global Health, Yu Fang and 
colleagues1 report the eﬀ ect of the reform on access to 
aﬀ ordable essential medicines in Shaanxi Province in 
western China.
Their main observation is that the availability of a 
standard basket of generic essential medicines in the 
public sector, which was already low in 2009 at 25·5%, 
further decreased to 20·5% in 2011. A similar decrease 
from 42·0% to 35·3% was seen with generic medicines 
in private pharmacies. At the same time the median 
price of 29 generic medicines fell, by 5·2% in the public 
sector and 4·7% in private pharmacies; the prices of 
16 originator brand products reduced by around 8–11% 
in both sectors.
This is the ﬁ rst longitudinal price and availability 
survey since 2009 to follow the standard WHO/Health 
Action International (HAI) protocol.2 It presents valuable 
information to national programme managers and 
health policy makers about the eﬀ ect of the health-
care reform. Yet the study has two limitations. First, the 
standard WHO/HAI basket of essential medicines might 
not be fully representative of usual prescribing practices 
in China. This point could underestimate availability 
because alternative medicines might be in stock. For 
example, amoxicillin tablets are produced by hundreds 
of local manufacturers in China. The survey only targeted 
the 500 mg strength, yet the 2012 Chinese Essential 
Medicines List recommends 125 mg and 250 mg.3 Low 
availability of the 500 mg strength might be misleading, 
since other strengths were probably available instead. 
The researchers mitigated this problem by adding 
17 locally preferred essential medicines to the study. 
Unfortunately, the availability of these proved as poor as 
the standard basket.
The second limitation is that the researchers present 
very few data on aﬀ ordability beyond reporting a price 
decrease corrected for inﬂ ation. Many other papers on 
the eﬀ ect of the health reform4,5 claim a positive eﬀ ect 
on access to medicines on the basis of price reduction. 
The paper by Fang and colleagues1 shows that such 
price reductions can come with signiﬁ cant decreases in 
availability. Price reductions mean little if the cheaper 
medicines are not available. The study therefore gives 
additional evidence that classic pricing policies often 
do not work for generic medicines. If maximum prices 
for generic medicines are imposed, local manufacturers 
might simply move production capacity towards 
products for which the prices are not controlled, such 
as non-essential medicines or unnecessary combination 
products; or focus on products for exportation.6
For price reductions to have a real eﬀ ect on 
aﬀ ordability, more is therefore needed. A 5–10% price 
reduction, as shown in this study, does not mean much 
if the product was excessively expensive in the ﬁ rst place. 
The link between price and aﬀ ordability also depends 
very much on income level. Shaanxi is a province 
in western China with a large proportion of rural 
inhabitants and large disparities in social and economic 
development between rural and urban areas. Within 
the three income levels studied in the province, the 
price of a medicine might be aﬀ ordable in one area and 
not in another. More detailed aﬀ ordability studies are 
therefore needed, linking the catastrophic expenditure 
potential of a medicine to various income percentiles, 
as done by Niëns and colleagues.7 For example, in the 
Philippines, originator-brand atenolol would push an 
additional 22% of the population below the lowest 
poverty line of US$1·25 per day, compared with 7% for 
the generic product.7 In China, the purchasing power 
of the new health insurance funds should now be used 
to the full to restrict reimbursement to medicines on 
the provincial list of essential medicines, and to limit 
the level of reimbursement to the median or mean 
price of available generic products of assured quality. 
Additionally, reimbursement should be linked to 
quality of care, by strengthening the links between the 
essential medicines list and agreed standard treatment 
guidelines. However, only when hospitals are no 
longer ﬁ nancially dependent on the sale of medicines 
will doctors no longer feel the pressure to prescribe 
medicines outside the reimbursement list.
What can we conclude from this excellent paper? First, 
the concept of essential medicines is not yet widely 
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accepted in this part of China, a ﬁ nding that is linked 
to the incomplete reform of the ﬁ nancing mechanism 
of public hospitals. Second, since the six areas in the 
province implemented the “zero-mark-up policy” in 
diﬀ erent stages between June, 2009, and the end of 
2011, a two time-point comparison can only paint a 
partial picture of the changes, and further longitudinal 
data are needed. Finally, detailed aﬀ ordability 
studies are also needed. These studies should include 
household consumption surveys, since with the current 
system the very poor might not use health facilities at 
all. Besides reporting on the level of catastrophic health 
expenditure, these studies should also record how the 
households have coped, for example by not starting 
the treatment, borrowing money, or selling economic 
assets such as cattle or land.8 Only such detailed 
information can convince and assist policy makers in 
ensuring access to aﬀ ordable essential medicines for all 
people in the province.
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